Angel Cedazo Minguez

My research is focused on understanding the molecular mechanism behind risk factor for neurodegenerative disorders. I combine my activities at KI with being Vice-president and Global Head of Translational Centers of Excellence at Sanofi. I am located in Paris (France). So far, I have published 100+ articles and directed 10+ PhD thesis. 

Positions
From 2017- present.  Professor in Molecular Neurogeriatrics, KI

From 2025- present  Vice-president. Global Head of Translational Centers of Excellence. SANOFI
From 2022- 2025  Vice-president. Strategic Initiatives and Scientific Relations. SANOFI
From 2017- 2022 Head of Neurodegeneration Research, SANOFI
From 2006- 2017 Deputy Head of KI-Alzheimer disease research center / Neurogeriatrics
From 2014- 2017 Codirector of Swedish Brain Power. A national network of centers of excellence in Neurodegenerative disorders.
From 2014- 2017 Vice-Head of the department of neurobiology, care sciences and society

Education
2017 Professor. Karolinska Institutet
2011 Senior University Lecturer. Karolinska Institutet.
2010 Associate Professor. Karolinska Institutet.
2010 Course for future academic leaders (MAL). Karolinska Institutet.
2002 Ph.D. in medicine (Neuroscience). Karolinska Institutet. Thesis: Apolipoprotein E and Alzheimer's disease: Signals and effects

Academic honours, awards and prizes
2013. Deputy Head (prefekt) of the Department of Neurobiology, Care Sciences and Society (NVS) at KI.
2009-2012. Vice-Head of the Department of Neurobiology, Care Sciences and Society at KI
2009- present. Member of the Committee for Research and Education at the Geriatric Department of the Swedish Medical Research Council (FoU råd)
2006, 2007 and 2008. Erik Rönnbergs award for research in geriatric medicine from the Bank of Sweden Tercentenary Foundation
2003 and 2004. Hjärnfonden postdoc (Swedish Brain Foundation)
2003. Svenska Lundbeck stiftelsen.

Over the years, genetic and epidemiological studies have identified numerous genetic and environmental factors that increase the risk of developing Alzheimer's disease (AD), suggesting that it is a condition of multifactorial origin.

Our objective is to contribute to the understanding of how these risk factors influence AD pathogenesis and to determine the extent to which they function as secondary contributors or primary drivers of cognitive decline. Our research encompasses mechanistic and translational investigations into the relationships between neurodegeneration and apolipoprotein E, hypercholesterolaemia, oxysterols, insulin resistance, and antioxidant pathways.